scholarly journals OPPORTUNITIES AND PROSPECTS FOR INCORPORATING A THIRD DRUG TO THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C

2013 ◽  
Vol 18 (5) ◽  
pp. 9-14
Author(s):  
T. V Sologub ◽  
V. V Tsvetkov ◽  
E. G Deeva ◽  
I. I Tokin
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Clinical Symptoms ◽  
Sustained Viral Response ◽  
Control Group ◽  
Genotype 1 ◽  
Viral Response ◽  
Hcv Genotype 1

In order to evaluate the efficiency and safety of using the drug Ingaron in treatment ofpatients with chronic hepatitis C (CHC) an open, randomized, control comparative study has been performed. We examined of 132 CHC patients aged from 18 to 58 years. All patients were selected into 3 groups depending on the type of therapy. The following drugs: Ribavirin, Alfarona, Ingaron were included in regimens of therapy. The course of the disease in examined CHC patients was characterized by mild clinical symptoms, the presence of the expressed cytolytic syndrome more than in half of the patients (50.8%), high levels of «viral load» in 61.6% of patients with the establishment of a direct correlation between high ALT and viremia levels (r=+0,67). The average level of «viral load» in patients infected with no-1 genotype of hepatitis C, at the start of therapy was 1,4 times higher than in those with genotype 1, amounting to 1,8 x 106 and 1,3 x 106 IU/ml, respectively. Patients infected with HCV genotype 1 and receiving therapy with Ingaron for 24 and 12 weeks, achieved sustained viral response in 65,0% and 80,0% of cases whereas patients infected with «no 1» genotype - in 73,9%, and 84,6% of cases, respectively. At the same time, in patients from the control group the sustained viral response was observed only in 56,0% and 60,0% of cases (1 and «no 1» genotypes, respectively). The inclusion of Ingaron into the classical medical regimen was accompanied by a reduction in the incidence of adverse reactions during treatment.

Pan-Asian Variability of Interleukin 28b (IL28B) Gene Polymorphism and Relationship to Sustained Viral Response (SVR) in Chronic Hepatitis C Genotype 1

2011 ◽  
Vol 140 (5) ◽  
pp. S-455-S-456
Author(s):  
P Patrick Basu ◽  
Niraj James Shah ◽  
Nithya Krishnaswamy ◽  
Sajith J. Foustin ◽  
Chris Tang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Gene Polymorphism ◽  
Chronic Hepatitis C ◽  
Sustained Viral Response ◽  
Genotype 1 ◽  
Viral Response ◽  
Interleukin 28B

scholarly journals Intrahepatic TLR3 and IFNL3 Expressions Are Associated with Stages of Fibrosis in Chronic Hepatitis C

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1103
Author(s):  
Keyla Santos Guedes de Sá ◽  
Ednelza da Silva Graça Amoras ◽  
Simone Regina Souza da Silva Conde ◽  
Maria Alice Freitas Queiroz ◽  
Izaura Maria Vieira Cayres-Vallinoto ◽  
...  
Keyword(s):  
Immune Response ◽  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Control Group ◽  
Gene Expressions ◽  
Healthy Control ◽  
Advanced Stages ◽  
Chronic Hcv

An inefficient immune response against the hepatitis C virus (HCV), combined with viral evasion mechanisms, is responsible for the chronicity of infection. The need to evaluate the innate mechanisms of the immune response, such as TLR3 and IFN-λ3, and their relationship with the virus–host interaction is important for understanding the pathogenesis of chronic hepatitis C. The present study aimed to investigate the gene expressions of TRL3 and IFNL3 in liver tissue, seeking to evaluate whether these could be potential biomarkers of HCV infection. A total of 23 liver biopsy samples were collected from patients with chronic HCV, and 8 biopsies were collected from healthy control patients. RNA extraction, reverse transcription and qPCR were performed to quantify the relative gene expressions of TLR3 and IFNL3. Data on the viral load; AST, ALT, GGT and AFP levels; and the viral genotype were collected from the patients′ medical records. The intrahepatic expression of TLR3 (p = 0.0326) was higher in chronic HCV carriers than in the control group, and the expression of IFNL3 (p = 0.0037) was lower in chronic HCV carriers than in the healthy control group. The expression levels of TLR3 (p = 0.0030) and IFNL3 (p = 0.0036) were higher in the early stages of fibrosis and of necroinflammatory activity in the liver; in contrast, TLR3 and IFNL3 expressions were lower in the more advanced stages of fibrosis and inflammation. There was no correlation between the gene expression and the serum viral load. Regarding the initial METAVIR scale scores, liver transaminase levels were lower in patients with advanced fibrosis when correlated with TLR3 and IFNL3 gene expressions. The results suggest that in the early stages of the development of hepatic fibrosis, TLR3 and IFN-λ3 play important roles in the antiviral response and in the modulation of the tolerogenic liver environment because there is a decrease in the intrahepatic expressions of TLR3 and IFNL3 in the advanced stages of fibrosis, probably due to viral evasion mechanisms.

scholarly journals IL-28B - Predictor of Sustained Virological Response for IFN-based Regimens in Chronic Hepatitis C and Criteria for Optimizing DAAs Indication

2019 ◽  
Vol 70 (11) ◽  
pp. 3964-3966
Author(s):  
Ioan Sergiu Micu ◽  
Marilena Musat ◽  
Yousef Al Hamidi ◽  
Andrada Dumitru ◽  
Anca Rogoveanu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Treatment Response ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Antiviral Treatment ◽  
Sustained Viral Response ◽  
Response Rates ◽  
Viral Response

Chronic viral infections affecting the liver represents a global burden for medical comunities. More than 170 million individuals are infected chronically with hepatitis C virus (HCV), this accounting about 2�3% of the world�s population. Despite numerous progresses aquired in viral pahogenesis and treatment, chronic hepatitis C management is influenced by a multitude of factors. Interleukin IL-28 beta subunit (IL28B) demonstrated to be involved in both sustained virological response (SVR) to treatment, but even with spontaneous viral clearance without any therapy. In the era of direct antiviral agents (DAAs) we aimed to find out what was the real influence of IL28B phenotypes over the response to Peg-IFN and Ribavirin treatment in patients with chronic hepatitis C, many of theses being non-responders or relapsers, and as consequence, to optimize the referal of patients to more expensive and efficient treatments. In a retrospectively manner, we analyzed the IL28B phenotype and its influence over the rapid viral response (RVR), early viral response (EVR) and sustained viral response (SVR), in 250 patients HCV treated patients. We made correlations between the treatment response rates and the IL28B polymorphism.TT phenotype was correlated negatively with all parameters studied, while CC phenotype was correlated with the best response rates. We concluded that IL28B phenotypes interfere with the EVR and SVR rates, IL28B phenotype being an independent prognostic factor for antiviral treatment response in our patient groups, and according to this characteristics, we created the premise to optimize the patients referal to expensive therapies as DAAs.

Sign in / Sign up

Export Citation Format

Share Document